In terms of revenue and profit, the Company achieved revenue of RMB 2.814 billion for the year, an increase of 19.15% year-on-year, net profit of RMB 431 million, an increase of 300.56% year-on-year, and basic earnings per share of RMB0.77.

In terms of assets, the Company's total assets at the end of the reporting period were RMB 4,617 million and accounts receivable were RMB 348 million. In terms of cash flow, net cash flow from operating activities was RMB 474 million and cash received from the sale of goods and provision of services was RMB 2,986 million.

About Sinocare

Sinocare has 21-year experience in Blood Glucose Monitor industry since its foundation in 2002. It is the biggest BGM manufacturing facility company in Asia and the first listed blood glucose meter company in China, dedicated to the innovation of biosensor technology, development, manufacturing, and marketing of rapid diagnostic testing products. In 2016, after the successful acquisition of Nipro diagnostic Inc. (now renamed Trividia Health Inc.) and PTS Diagnostics Inc., Sinocare had become the world's No.5 largest blood glucose meter manufacturer and one of the leading companies in the POCT industry in the world.

Sinocare Lu Valley Biosensor Manufacturing Facility, located in Changsha National High-Tech Industrial Development Zone, was launched in 2013. With around 66,000 m2 gross area, our factory has become the biggest Blood Glucose Monitoring System (BGMS) production base in Asia. Now Sinocare occupies more than 63% OTC share and 130,000 pharmacies in China. Sinocare’s business covers 135 countries and regions, manufacturing products include blood glucose, blood lipids, blood ketone, glycosylated hemoglobin (HbA1c), uric acid, and other diabetes indicators.